WSJ explores potential impact of biosimilars on biotech drug market

The Wall Street Journal is examining the potential that biosimilars can have in the market for biotechnology drugs by looking at how they have been received in Europe to highlight their potential in the U.S. following the launch of Zarxio, the first U.S. biosimilar, earlier this month.